Dr. Reddy's Laboratories

OverviewSuggest Edit

Dr. Reddy’s Laboratories (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) business and custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL’s new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma. On March 27, 2012, DRL launched quetiapine fumarate tablets. On March 2, 2012, it launched ziprasidone hydrochloride capsules. On October 24, 2011, DRL launched olanzapine tablets. On July 25, 2011, it launched fondaparinux sodium injection.
TypePublic
Founded1984
HQHyderabad, IN
Websitedrreddys.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Sept 2020)21,650
Job Openings12
Share Price (Sept 2020)₹5.3 K(+11%)
Cybersecurity ratingFMore

Key People/Management at Dr. Reddy's Laboratories

Satish Reddy

Satish Reddy

Chairman
Sandeep Poddar

Sandeep Poddar

Company Secretary
Prasad Raghava Menon

Prasad Raghava Menon

Chairman
Shikha Sharma

Shikha Sharma

Chairman
Bruce Carter

Bruce Carter

Chairman
Bharat Narotam Doshi

Bharat Narotam Doshi

Chairman
Show more

Dr. Reddy's Laboratories Office Locations

Dr. Reddy's Laboratories has offices in Hyderabad, Jinnaram, Nalgonda, Pimpri-Chinchwad and in 29 other locations
Hyderabad, IN (HQ)
8-2-268/A/2/19, Banjara Hills Rd Number 3, Venkateshwara Nagar, Aurora Colony, Banjara Hills
Hyderabad, IN
1 plot no. 137, 1-38, Industrial Development Area Bollaram, Bollaram
Hyderabad, IN
42, 2-45, Maheshwaram, Bachupally
Pimpri-Chinchwad, IN
Sector No. 28, Pradhikaran, Nigdi
Melbourne, AU
suite 3. 03, level/390 St Kilda Rd
Mississauga, CA
204-5580 Explorer Dr
Show all (41)

Dr. Reddy's Laboratories Financials and Metrics

Dr. Reddy's Laboratories Revenue

Market capitalization (18-Sept-2020)

884.6b

Closing stock price (18-Sept-2020)

5.3k
Dr. Reddy's Laboratories's current market capitalization is ₹884.6 b.
Show all financial metrics

Dr. Reddy's Laboratories Cybersecurity Score

Cybersecurity ratingPremium dataset

F

54/100

SecurityScorecard logo

Dr. Reddy's Laboratories Online and Social Media Presence

Embed Graph

Dr. Reddy's Laboratories News and Updates

Nuvo Pharmaceuticals™ Announces United States District Court Denies Dr. Reddy's Laboratories Motion for Summary Judgment of Nuvo's '996 and '920 VIMOVO Patents

VIMOVO Litigation to Continue MISSISSAUGA, ON, Nov. 11, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that the United...

URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders or Former Shareholders To Contact the Firm Immediately

NEW YORK, May 1, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City announces that it is investigating Dr. Reddy's Laboratories Ltd., (NYSE: RDY) ("Dr....

Global $200+ Billion Drug API Market Forecasts to 2024 with Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Aurobindo Pharma and Cipla Dominating

DUBLIN, April 24, 2019 /PRNewswire/ -- The "Drug API Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering. The global drug API market is projected to grow at a CAGR of 5.40% to reach US$200.385 billion by 2024, from US$146.141 billion in 2018....

Global Biosimilars Market 2017-2019 & 2024: Total of 492 Products in Development Featuring Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Pfizer, Samsung Bioepis & Sandoz

DUBLIN, Jan. 22, 2019 /PRNewswire/ -- The "Global Biosimilars Market - Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics" report has been added to ResearchAndMarkets.com's offering. The Global Biosimilar market by product...

Dr. Reddy's Laboratories launches Chlorthalidone Tablets in US market

The Hygroton brand and generic had U.S. sales of approximately $122 million MAT for the most recent twelve months ending in September 2018 according to IMS Health.
Show more

Dr. Reddy's Laboratories Frequently Asked Questions

  • When was Dr. Reddy's Laboratories founded?

    Dr. Reddy's Laboratories was founded in 1984.

  • Who are Dr. Reddy's Laboratories key executives?

    Dr. Reddy's Laboratories's key executives are Satish Reddy, Sandeep Poddar and Prasad Raghava Menon.

  • How many employees does Dr. Reddy's Laboratories have?

    Dr. Reddy's Laboratories has 21,650 employees.

  • Who are Dr. Reddy's Laboratories competitors?

    Competitors of Dr. Reddy's Laboratories include Cipla, Neumentum and Integrated Prescription Management.

  • Where is Dr. Reddy's Laboratories headquarters?

    Dr. Reddy's Laboratories headquarters is located at 8-2-268/A/2/19, Banjara Hills Rd Number 3, Venkateshwara Nagar, Aurora Colony, Banjara Hills, Hyderabad.

  • Where are Dr. Reddy's Laboratories offices?

    Dr. Reddy's Laboratories has offices in Hyderabad, Jinnaram, Nalgonda, Pimpri-Chinchwad and in 29 other locations.

  • How many offices does Dr. Reddy's Laboratories have?

    Dr. Reddy's Laboratories has 41 offices.